R&D Milestones, Response on Published Reports, and Independent Clinical Programs Widen Growth Opportunities for Biotech Companies - Research Report on Verastem, Acorda, Hyperion, XOMA, and Lexicon

NEW YORK, July 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Verastem, Inc. (NASDAQ: VSTM), Acorda Therapeutics (NASDAQ: ACOR), Hyperion Therapeutics, Inc. (NASDAQ: HPTX), XOMA Corporation (NASDAQ: XOMA), and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Verastem, Inc. Research Report

On June 27, 2013, Verastem, Inc. (Verastem) announced that it has successfully completed the Phase I stage of combination trial of VS-6063 and paclitaxel. Manish Patel, M.D., Principal Investigator, Florida Cancer Specialists, said, "The combination of VS-6063 and weekly paclitaxel has been well tolerated, with no unexpected toxicity, and no worsening of the well understood side effects of paclitaxel." Patel continued, "The observation that 3 of the 4 patients continuing on study have had a significant reduction in the CA-125 level is encouraging." Robert Forrester, President and Chief Operating Officer of Verastem, stated, "With the completion of the dose escalation stage, we are now initiating an expansion cohort of patients with ovarian cancer to further evaluate the activity of the combination therapy. Importantly, the ability to combine VS-6063 with paclitaxel provides an opportunity to explore multiple additional indications where the tumors are driven by cancer stem cells and paclitaxel is the standard of care." The Full Research Report on Verastem, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/cbde_VSTM]

--

Acorda Therapeutics, Inc. Research Report

On June 26, 2013, Acorda Therapeutics, Inc. (Acorda) announced the results of its first clinical study to assess pharmacokinetics, safety and tolerability of Diazepam Nasal Spray in people with epilepsy. According to the Company, the Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures or acute repetitive seizures. Enrique Carrazana, M.D., Chief Medical Officer of Acorda, stated, "The study results showed that the Diazepam Nasal Spray pharmacokinetics are comparable whether it is administered during or immediately following a seizure. For people with epilepsy who experience cluster seizures, it is critical that treatment be administered as soon as a cluster is recognized, to prevent additional seizure activity." Carrazana added, "Diazepam Nasal Spray offers a therapeutic alternative that can be administered rapidly and conveniently." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/de76_ACOR]

--

Hyperion Therapeutics, Inc. Research Report

On June 18, 2013, Hyperion Therapeutics, Inc. (Hyperion) announced that the population pharmacokinetic (PK) modeling and dosing simulations based on the data from its Phase II and III trials were included in The Journal of Clinical Pharmacology. The Phase II and III trials collectively enrolled patients with urea cycle disorders (UCDs) of ages 2 months to 72 years. Bruce Scharschmidt, MD, Chief Medical Officer of Hyperion, stated, "This work represents an outstanding example of how population PK modeling and dosing simulations can be used to help understand the behavior of drugs for patients with rare diseases in which large trials are not feasible. We are pleased to provide the UCD community with options to treat this serious disease. Specifically, with our launch of RAVICTI earlier this year, patients now have access to an important new option." The Full Research Report on Hyperion Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/5225_HPTX]

--

XOMA Corporation Research Report

On June 25, 2013, XOMA Corporation (XOMA) announced that SERVIER, its development partner, has launched its own independent Proof-of-Concept (POC) clinical program to evaluate the safety and efficacy of gevokizumab. XOMA stated that it had launched a similar POC clinical program in November 2011, which included studies in three separate indications, including moderate to severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the hand, and non-anterior scleritis. The Company reported that SERVIER has selected several indications across multiple therapeutic areas. "We are impressed with the breadth and depth of SERVIER's development plan. The first indication they are studying is polymyositis/dermatomyositis. Once SERVIER's POC program is fully underway, we anticipate gevokizumab will be undergoing safety and efficacy evaluations in over a dozen potential indications between SERVIER's and our efforts," commented John Varian, CEO of XOMA. The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/9e50_XOMA]

--

Lexicon Pharmaceuticals, Inc. Research Report

On June 24, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon) announced that it presented the first publication of data on LX2761 during the 73rd Scientific Sessions of the American Diabetes Association (ADA). Alan Main, Ph.D., Executive Vice President of Pharmaceutical Research at Lexicon, said, "LX2761 was designed to act locally in the gastrointestinal tract to reduce glucose absorption by inhibiting SGLT1 without any significant inhibition of SGLT2 in the kidney." Main continued, "This was accomplished through a dedicated medicinal chemistry effort to identify molecules with limited systemic exposure that showed efficacy in animal models of diabetes." Brian Zambrowicz, Ph.D., Executive Vice President and Chief Scientific Officer at Lexicon, commented, "We hope LX2761 may one day treat a large population of patients with diabetes, and potentially prediabetes, that may wish to avoid the urinary glucose excretion associated with SGLT2 inhibition in the kidney." Zambrowicz added, "In addition, the synergy demonstrated with a DPP-4 inhibitor provides the mechanistic rationale to consider future combination therapies." The Full Research Report on Lexicon Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/b93b_LXRX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports